A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted Therapy
Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC...
Saved in:
Published in | Advanced materials (Weinheim) Vol. 32; no. 28; pp. e1908435 - n/a |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.07.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems.
Carboxylated azocalix[4]arene is designed as a hypoxia‐responsive molecular container, which affords strong binding toward a series of chemotherapeutic drugs, and improves the drugs’ solubility and stability, demonstrating its universality as a supramolecular drug carrier. Taking one supramolecular prodrug as an example, the efficacy of this hypoxia‐targeted therapy is validated in vitro and in vivo. |
---|---|
AbstractList | Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems. Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia-responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia-targeted drug-delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor-targeted drug-release with reduced side effects. CAC4A fulfils all essential requirements for a drug-delivery system in addition to multiple advantages, including facile preparation, well-defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench-to-bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug-delivery systems.Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia-responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia-targeted drug-delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor-targeted drug-release with reduced side effects. CAC4A fulfils all essential requirements for a drug-delivery system in addition to multiple advantages, including facile preparation, well-defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench-to-bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug-delivery systems. Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems. Carboxylated azocalix[4]arene is designed as a hypoxia‐responsive molecular container, which affords strong binding toward a series of chemotherapeutic drugs, and improves the drugs’ solubility and stability, demonstrating its universality as a supramolecular drug carrier. Taking one supramolecular prodrug as an example, the efficacy of this hypoxia‐targeted therapy is validated in vitro and in vivo. |
Author | Yue, Yu‐Xin Shi, Linqi Guo, Dong‐Sheng Hu, Xin‐Yue Liu, Yang Zhang, Tian‐Xing Zhang, Zhan‐Zhan Huang, Fan |
Author_xml | – sequence: 1 givenname: Tian‐Xing surname: Zhang fullname: Zhang, Tian‐Xing organization: Nankai University – sequence: 2 givenname: Zhan‐Zhan surname: Zhang fullname: Zhang, Zhan‐Zhan organization: Nankai University – sequence: 3 givenname: Yu‐Xin surname: Yue fullname: Yue, Yu‐Xin organization: Nankai University – sequence: 4 givenname: Xin‐Yue surname: Hu fullname: Hu, Xin‐Yue organization: Nankai University – sequence: 5 givenname: Fan surname: Huang fullname: Huang, Fan email: huangfan@irm-cams.ac.cn organization: Chinese Academy of Medical Science & Peking Union Medical College – sequence: 6 givenname: Linqi surname: Shi fullname: Shi, Linqi email: shilinqi@nankai.edu.cn organization: Nankai University – sequence: 7 givenname: Yang surname: Liu fullname: Liu, Yang email: yliu@nankai.edu.cn organization: Nankai University – sequence: 8 givenname: Dong‐Sheng orcidid: 0000-0002-0765-5427 surname: Guo fullname: Guo, Dong‐Sheng email: dshguo@nankai.edu.cn organization: Nankai University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32459030$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1P3DAQhq0KVJaPa48oUi-97DL-iuPjals-JBBStT1HXmdSjJI4tZPC3vgJ_EZ-CV4tpRIS4jCay_PMjObdJzud75CQLxRmFICdmKo1MwZUQyG4_EQmVDI6FaDlDpmA5nKqc1Hskf0YbwFA55B_JnucCamBw4Rcz7Mz7DCYJjtf9_7emaeHx58Ye99F9xezK9-gHRsTsoXvBuMSmtU-ZMux9SGhSxN-44BVtrxJQ_r1IdmtTRPx6KUfkF-nP5aL8-nl9dnFYn45tVxtjmKyyK2orcpXBa-0LpRd1UoqhcAFM8hMbWvOKk1FUdSVVIYzC6JgtBIoDD8g37Zz--D_jBiHsnXRYtOYDv0YSyZAcaqEkgn9-ga99WPo0nWJYlxSSJWo4xdqXLVYlX1wrQnr8t-rEjDbAjb4GAPWrwiFcpNFucmifM0iCeKNYN1gBpf-GIxr3tf0VrtzDa4_WFLOv1_N_7vPXGSeaQ |
CitedBy_id | crossref_primary_10_1002_advs_202104349 crossref_primary_10_1002_ps_7492 crossref_primary_10_1021_acsnano_4c01939 crossref_primary_10_1021_acs_molpharmaceut_2c01079 crossref_primary_10_1021_acsnano_3c04718 crossref_primary_10_1021_acs_analchem_2c00406 crossref_primary_10_1002_anie_202213578 crossref_primary_10_1016_j_biomaterials_2022_121599 crossref_primary_10_1515_mr_2022_0048 crossref_primary_10_1093_rb_rbad087 crossref_primary_10_3390_s24227181 crossref_primary_10_1002_adhm_202302940 crossref_primary_10_1021_acs_analchem_1c03153 crossref_primary_10_1021_acsanm_4c00826 crossref_primary_10_1039_D3CC04159J crossref_primary_10_1002_adma_202100114 crossref_primary_10_1039_D3SC00107E crossref_primary_10_1016_j_nantod_2024_102373 crossref_primary_10_1002_ange_202402139 crossref_primary_10_1002_adtp_202400207 crossref_primary_10_1021_acsmaterialslett_4c02496 crossref_primary_10_1002_adma_202206851 crossref_primary_10_1038_s41467_022_33920_7 crossref_primary_10_1038_s41467_025_55905_y crossref_primary_10_1038_s41467_025_56308_9 crossref_primary_10_1002_wnan_70001 crossref_primary_10_1021_accountsmr_3c00130 crossref_primary_10_3390_s24123743 crossref_primary_10_1038_s41467_022_30012_4 crossref_primary_10_1021_acsami_3c08703 crossref_primary_10_1002_adfm_202213967 crossref_primary_10_1002_cbic_202400426 crossref_primary_10_1186_s12951_023_02062_3 crossref_primary_10_1002_advs_202309517 crossref_primary_10_1007_s11426_024_1971_4 crossref_primary_10_1039_D3MH00018D crossref_primary_10_1016_j_arabjc_2023_104974 crossref_primary_10_1039_D1SC01888D crossref_primary_10_1007_s10847_023_01200_6 crossref_primary_10_1039_D0SC05525E crossref_primary_10_1039_D0MA00625D crossref_primary_10_1039_D3TB02432F crossref_primary_10_1080_10717544_2021_2021324 crossref_primary_10_1016_j_ijbiomac_2024_132579 crossref_primary_10_1021_acsnano_4c05693 crossref_primary_10_1007_s11426_024_2231_1 crossref_primary_10_1002_adhm_202401778 crossref_primary_10_1021_acsami_4c09588 crossref_primary_10_1002_mabi_202400626 crossref_primary_10_3390_nano14100864 crossref_primary_10_1002_anie_202009442 crossref_primary_10_1016_j_nantod_2023_102064 crossref_primary_10_1021_acsnano_3c09140 crossref_primary_10_1002_ange_202213578 crossref_primary_10_1002_anie_202008732 crossref_primary_10_1002_adma_202304246 crossref_primary_10_1021_acsnano_1c09505 crossref_primary_10_1002_adma_202304249 crossref_primary_10_1016_j_colsurfb_2024_114383 crossref_primary_10_1002_bkcs_12655 crossref_primary_10_1021_acs_accounts_3c00585 crossref_primary_10_1002_ange_202315990 crossref_primary_10_1002_smll_202202834 crossref_primary_10_1126_sciadv_adp9071 crossref_primary_10_1002_adhm_202201889 crossref_primary_10_1002_anie_202402139 crossref_primary_10_1126_sciadv_adk0716 crossref_primary_10_3390_ijms232314889 crossref_primary_10_1039_D4TB02400A crossref_primary_10_1002_ange_202009442 crossref_primary_10_1002_smll_202006223 crossref_primary_10_1039_D2NA00420H crossref_primary_10_1002_adma_202403296 crossref_primary_10_1002_advs_202404731 crossref_primary_10_1002_adhm_202400747 crossref_primary_10_1002_adtp_202100176 crossref_primary_10_1039_D3CC01405C crossref_primary_10_3390_molecules26185451 crossref_primary_10_1002_anse_202300082 crossref_primary_10_3390_molecules28031241 crossref_primary_10_3390_molecules26133963 crossref_primary_10_1002_adma_202203765 crossref_primary_10_1002_adma_202007719 crossref_primary_10_3389_fchem_2021_710808 crossref_primary_10_1002_adma_202207733 crossref_primary_10_1038_s41467_023_41388_2 crossref_primary_10_1002_anie_202315990 crossref_primary_10_1039_D3NR02968A crossref_primary_10_1002_smll_202205440 crossref_primary_10_1002_ange_202008732 crossref_primary_10_1007_s12274_022_4332_4 crossref_primary_10_1007_s11426_023_1857_2 crossref_primary_10_1016_j_actbio_2022_05_050 crossref_primary_10_1002_adma_202105348 crossref_primary_10_1021_jacs_2c08144 crossref_primary_10_1002_smll_202100578 crossref_primary_10_1016_j_jconrel_2024_03_017 crossref_primary_10_1021_acsami_3c11626 crossref_primary_10_1002_agt2_3 crossref_primary_10_1039_D2OB00656A crossref_primary_10_1021_jacs_4c03238 crossref_primary_10_1007_s11426_024_2301_3 crossref_primary_10_3390_ph16050699 crossref_primary_10_1021_acsami_4c13762 crossref_primary_10_1002_sstr_202200067 crossref_primary_10_1016_j_colsurfb_2023_113395 crossref_primary_10_1021_acs_nanolett_1c00488 crossref_primary_10_1021_acsabm_1c00847 crossref_primary_10_1021_jacs_1c13067 crossref_primary_10_1021_acs_biomac_4c00722 crossref_primary_10_3390_molecules29163828 |
Cites_doi | 10.1002/anie.201709002 10.1016/j.ijpharm.2006.10.044 10.3109/01480545.2011.653490 10.1111/j.1349-7006.2003.tb01395.x 10.1021/cr500392w 10.1002/adma.201203229 10.1039/C7SC04989G 10.1002/anie.199507131 10.1021/acsami.7b19784 10.1002/adma.201703444 10.1021/acs.chemrev.6b00525 10.1021/acs.chemrev.8b00401 10.1039/C5BM00532A 10.1021/j100096a001 10.1021/ja071090b 10.1021/nn201171r 10.1038/nrc3064 10.1016/S1369-7021(11)70161-4 10.7150/thno.31914 10.1039/C7CS00391A 10.1111/j.2042-7158.2012.01567.x 10.1039/b504487a 10.1039/c000605j 10.1039/C8CS00271A 10.1039/c1sc00231g 10.1111/j.1365-2230.2010.03989.x 10.1038/nnano.2011.166 10.1002/anie.201511432 10.1063/1.1677527 10.1039/C7CP02110K 10.1073/pnas.1204600109 10.1021/acsami.7b01157 10.1016/j.addr.2007.05.006 10.1002/chem.200900165 10.1016/j.addr.2012.01.015 10.1021/acs.chemrev.5b00046 10.1021/cr970025p 10.1007/s10847-014-0412-8 10.1039/C2CS35233H 10.1007/BF00533485 10.1038/s41565-018-0146-7 10.1021/cr200213s 10.1039/C8CS00037A 10.1016/j.addr.2007.05.012 10.1021/ar2000259 10.1038/s41557-018-0164-y 10.1111/cbdd.12818 10.7150/thno.31653 10.1039/C3PY01202F 10.1039/C7CS90102J 10.1002/anie.201813397 10.1038/nchem.1326 10.1039/b813759e 10.1038/nnano.2010.231 10.1038/natrevmats.2016.75 10.1038/nmat2992 10.1002/wnan.1527 10.1021/cr2001178 10.1016/j.addr.2008.02.011 10.1039/C8CS00304A 10.1002/wcms.19 10.1063/1.464913 10.1002/anie.201707164 10.1038/s41570-017-0063 10.1002/adma.201805697 10.1016/S1773-2247(04)50001-1 10.1039/c0nj00285b 10.1039/C6CS00898D 10.1021/ac5039779 10.1007/978-0-387-46312-4 10.1039/C7SC01438D 10.1002/ijch.201900032 10.1021/acs.chemrev.5b00341 10.1021/jacs.8b02331 10.1021/jo00039a027 10.1002/ijch.201100033 10.1074/jbc.273.24.14721 10.1038/nmat3430 10.1016/0022-1759(83)90303-4 |
ContentType | Journal Article |
Copyright | 2020 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Copyright_xml | – notice: 2020 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim – notice: 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
DBID | AAYXX CITATION NPM 7SR 8BQ 8FD JG9 7X8 |
DOI | 10.1002/adma.201908435 |
DatabaseName | CrossRef PubMed Engineered Materials Abstracts METADEX Technology Research Database Materials Research Database MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed Materials Research Database Engineered Materials Abstracts Technology Research Database METADEX MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed MEDLINE - Academic Materials Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1521-4095 |
EndPage | n/a |
ExternalDocumentID | 32459030 10_1002_adma_201908435 ADMA201908435 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: National Key Research and Development Programs of China funderid: 2018YFA0209700 – fundername: Fundamental Research Funds for the Central Universities – fundername: NSFC funderid: 51873090; 31961143004; 21620102005 – fundername: NSFC grantid: 51873090 – fundername: NSFC grantid: 31961143004 – fundername: National Key Research and Development Program of China grantid: 2018YFA0209700 – fundername: NSFC grantid: 21620102005 |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23M 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ACAHQ ACCFJ ACCZN ACGFS ACIWK ACPOU ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM EBS F00 F01 F04 F5P G-S G.N GNP GODZA H.T H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RWM RX1 RYL SUPJJ TN5 UB1 UPT V2E W8V W99 WBKPD WFSAM WIB WIH WIK WJL WOHZO WQJ WRC WXSBR WYISQ XG1 XPP XV2 YR2 ZZTAW ~02 ~IA ~WT .Y3 31~ 6TJ 8WZ A6W AANHP AAYOK AAYXX ABEML ACBWZ ACRPL ACSCC ACYXJ ADMLS ADNMO AETEA AEYWJ AFFNX AGHNM AGQPQ AGYGG ASPBG AVWKF AZFZN CITATION EJD FEDTE FOJGT HF~ HVGLF LW6 M6K NDZJH PALCI RIWAO RJQFR SAMSI WTY ZY4 NPM 7SR 8BQ 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY JG9 7X8 |
ID | FETCH-LOGICAL-c3735-92586c4fc76b83d9987cbf7577e0342ae2afcf32d91488fd57a32c04821d4e4a3 |
IEDL.DBID | DR2 |
ISSN | 0935-9648 1521-4095 |
IngestDate | Fri Jul 11 11:05:11 EDT 2025 Fri Jul 25 04:54:15 EDT 2025 Wed Feb 19 02:29:51 EST 2025 Thu Apr 24 22:53:05 EDT 2025 Tue Jul 01 02:32:48 EDT 2025 Wed Jan 22 16:34:37 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 28 |
Keywords | hypoxia drug delivery calixarene chemotherapy supramolecular chemistry |
Language | English |
License | 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3735-92586c4fc76b83d9987cbf7577e0342ae2afcf32d91488fd57a32c04821d4e4a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-0765-5427 |
PMID | 32459030 |
PQID | 2423510351 |
PQPubID | 2045203 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2407317475 proquest_journals_2423510351 pubmed_primary_32459030 crossref_primary_10_1002_adma_201908435 crossref_citationtrail_10_1002_adma_201908435 wiley_primary_10_1002_adma_201908435_ADMA201908435 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-07-01 |
PublicationDateYYYYMMDD | 2020-07-01 |
PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | Advanced materials (Weinheim) |
PublicationTitleAlternate | Adv Mater |
PublicationYear | 2020 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2018 2017 2017 2017 2018; 140 56 9 8 10 2019; 9 2007; 129 1994 1993 1973 1972; 98 98 28 56 2011; 1 2017 2004 2011 2008 2017 2017; 46 14 51 60 46 46 2019; 31 2018 2017 2014 2019 2010 2018 2019; 47 89 80 9 34 9 11 2013; 65 2013 2008 2012; 36 6 4 1995; 34 2013; 42 2019; 58 2011; 10 2006 1992; 57 2017 2019; 117 48 2011; 36 2011; 6 2011; 5 2007; 59 2018; 47 2012 2012 2011; 112 11 44 1998; 273 2016; 55 2016; 4 2012 2011 2013; 109 14 25 1998 2007; 98 329 2014; 5 2017 2019 2019 2015 2015 2019 2017; 1 119 11 115 115 59 2 2003 2011 2015; 94 11 87 2011 2011; 2 111 2010; 46 2015; 115 2017; 56 1983; 65 2018; 30 2017; 19 2005; 3 2010; 5 2012; 64 2009; 15 2018; 13 e_1_2_4_40_1 e_1_2_4_21_1 e_1_2_4_44_1 e_1_2_4_23_1 e_1_2_4_42_1 e_1_2_4_21_2 e_1_2_4_25_1 e_1_2_4_27_1 e_1_2_4_27_3 e_1_2_4_29_1 e_1_2_4_27_2 e_1_2_4_27_4 e_1_2_4_1_1 e_1_2_4_1_3 e_1_2_4_3_1 e_1_2_4_1_2 e_1_2_4_1_5 e_1_2_4_5_1 e_1_2_4_1_4 e_1_2_4_1_7 e_1_2_4_7_1 e_1_2_4_1_6 e_1_2_4_9_1 e_1_2_4_31_2 e_1_2_4_10_1 e_1_2_4_31_1 e_1_2_4_12_1 e_1_2_4_31_3 e_1_2_4_33_1 e_1_2_4_14_1 e_1_2_4_35_1 e_1_2_4_16_1 e_1_2_4_37_2 e_1_2_4_37_1 e_1_2_4_18_1 e_1_2_4_39_1 e_1_2_4_18_2 e_1_2_4_41_1 e_1_2_4_20_2 e_1_2_4_20_1 e_1_2_4_45_1 e_1_2_4_20_3 e_1_2_4_22_1 e_1_2_4_43_1 e_1_2_4_24_2 e_1_2_4_24_1 e_1_2_4_24_4 e_1_2_4_24_3 e_1_2_4_26_1 e_1_2_4_24_6 e_1_2_4_24_5 e_1_2_4_28_1 e_1_2_4_24_7 e_1_2_4_2_1 e_1_2_4_4_1 e_1_2_4_6_1 e_1_2_4_8_2 e_1_2_4_8_1 e_1_2_4_8_3 e_1_2_4_30_1 e_1_2_4_32_1 e_1_2_4_11_1 e_1_2_4_34_1 e_1_2_4_11_2 e_1_2_4_11_3 e_1_2_4_13_1 e_1_2_4_36_1 e_1_2_4_13_2 e_1_2_4_13_3 e_1_2_4_15_1 e_1_2_4_38_1 e_1_2_4_13_4 e_1_2_4_13_5 e_1_2_4_13_6 e_1_2_4_17_1 e_1_2_4_19_2 e_1_2_4_19_1 e_1_2_4_19_4 e_1_2_4_19_3 e_1_2_4_19_5 |
References_xml | – volume: 59 start-page: 645 year: 2007 publication-title: Adv. Drug Delivery Rev. – volume: 2 111 start-page: 1722 7941 year: 2011 2011 publication-title: Chem. Sci. Chem. Rev. – volume: 47 start-page: 5491 year: 2018 publication-title: Chem. Soc. Rev. – volume: 58 start-page: 2377 year: 2019 publication-title: Angew. Chem., Int. Ed. – volume: 46 start-page: 3188 year: 2010 publication-title: Chem. Commun. – volume: 3 start-page: 2122 year: 2005 publication-title: Org. Biomol. Chem. – volume: 9 start-page: 3041 year: 2019 publication-title: Theranostics – volume: 1 start-page: 153 year: 2011 publication-title: Wiley Interdiscip. Rev.: Comput. Mol. Sci. – volume: 56 year: 2017 publication-title: Angew. Chem., Int. Ed. – volume: 117 48 start-page: 6160 771 year: 2017 2019 publication-title: Chem. Rev. Chem. Soc. Rev. – volume: 109 14 25 start-page: 316 168 year: 2012 2011 2013 publication-title: Proc. Natl. Acad. Sci. USA Mater. Today Adv. Mater. – volume: 47 89 80 9 34 9 11 start-page: 7006 243 189 3094 2715 2087 86 year: 2018 2017 2014 2019 2010 2018 2019 publication-title: Chem. Soc. Rev. Chem. Biol. Drug Des. J. Inclusion Phenom. Macrocyclic Chem. Theranostics New J. Chem. Chem. Sci. Nat. Chem. – volume: 42 start-page: 366 year: 2013 publication-title: Chem. Soc. Rev. – volume: 64 start-page: 764 year: 2012 publication-title: Adv. Drug Delivery Rev. – volume: 112 11 44 start-page: 2739 1038 893 year: 2012 2012 2011 publication-title: Chem. Rev. Nat. Mater. Acc. Chem. Res. – volume: 94 11 87 start-page: 1021 393 1274 year: 2003 2011 2015 publication-title: Cancer Sci.. Nat. Rev. Cancer Anal. Chem. – volume: 34 start-page: 713 year: 1995 publication-title: Angew. Chem., Int. Ed. Engl. – volume: 15 start-page: 5301 year: 2009 publication-title: Chem. ‐ Eur. J. – volume: 13 start-page: 746 year: 2018 publication-title: Nat. Nanotechnol. – volume: 129 start-page: 5362 year: 2007 publication-title: J. Am. Chem. Soc. – volume: 1 119 11 115 115 59 2 start-page: 0063 1666 1527 7794 913 year: 2017 2019 2019 2015 2015 2019 2017 publication-title: Nat. Rev. Chem. Chem. Rev. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. Chem. Rev. Chem. Rev. Isr. J. Chem. Nat. Rev. Mater. – volume: 10 start-page: 389 year: 2011 publication-title: Nat. Mater. – volume: 31 year: 2019 publication-title: Adv. Mater. – volume: 4 start-page: 375 year: 2016 publication-title: Biomater. Sci. – volume: 19 year: 2017 publication-title: Phys. Chem. Chem. Phys. – volume: 59 start-page: 667 year: 2007 publication-title: Adv. Drug Delivery Rev. – volume: 65 start-page: 157 year: 2013 publication-title: J. Pharm. Pharmacol. – volume: 5 start-page: 1503 year: 2014 publication-title: Polym. Chem. – volume: 57 start-page: 3658 year: 1992 publication-title: J. Org. Chem. – volume: 30 year: 2018 publication-title: Adv. Mater. – volume: 5 start-page: 5094 year: 2011 publication-title: ACS Nano – volume: 115 year: 2015 publication-title: Chem. Rev. – year: 2006 – volume: 36 start-page: 645 year: 2011 publication-title: Clin. Exp. Dermatol. – volume: 6 start-page: 815 year: 2011 publication-title: Nat. Nanotechnol. – volume: 5 start-page: 833 year: 2010 publication-title: Nat. Nanotechnol. – volume: 98 98 28 56 start-page: 5648 213 2257 year: 1994 1993 1973 1972 publication-title: J. Phys. Chem. J. Chem. Phys. Theor. Chim. Acta J. Chem. Phys. – volume: 65 start-page: 55 year: 1983 publication-title: J. Immunol. Methods – volume: 273 year: 1998 publication-title: J. Biol. Chem. – volume: 55 start-page: 2792 year: 2016 publication-title: Angew. Chem., Int. Ed. – volume: 46 14 51 60 46 46 start-page: 6600 3 616 1000 6430 7021 year: 2017 2004 2011 2008 2017 2017 publication-title: Chem. Soc. Rev. J. Drug Delivery Sci. Technol. Isr. J. Chem. Adv. Drug Delivery Rev. Chem. Soc. Rev. Chem. Soc. Rev. – volume: 36 6 4 start-page: 119 4509 503 year: 2013 2008 2012 publication-title: Drug Chem. Toxicol. Org. Biomol. Chem. Nat. Chem. – volume: 98 329 start-page: 2045 1 year: 1998 2007 publication-title: Chem. Rev. Int. J. Pharm. – volume: 140 56 9 8 10 start-page: 4945 8602 4458 5365 year: 2018 2017 2017 2017 2018 publication-title: J. Am. Chem. Soc. Angew. Chem., Int. Ed. ACS Appl. Mater. Interfaces Chem. Sci. ACS Appl. Mater. Interfaces – ident: e_1_2_4_12_1 doi: 10.1002/anie.201709002 – ident: e_1_2_4_18_2 doi: 10.1016/j.ijpharm.2006.10.044 – ident: e_1_2_4_31_1 doi: 10.3109/01480545.2011.653490 – ident: e_1_2_4_20_1 doi: 10.1111/j.1349-7006.2003.tb01395.x – ident: e_1_2_4_1_4 doi: 10.1021/cr500392w – ident: e_1_2_4_11_3 doi: 10.1002/adma.201203229 – ident: e_1_2_4_24_6 doi: 10.1039/C7SC04989G – ident: e_1_2_4_23_1 doi: 10.1002/anie.199507131 – ident: e_1_2_4_19_5 doi: 10.1021/acsami.7b19784 – ident: e_1_2_4_5_1 doi: 10.1002/adma.201703444 – ident: e_1_2_4_21_1 doi: 10.1021/acs.chemrev.6b00525 – ident: e_1_2_4_1_2 doi: 10.1021/acs.chemrev.8b00401 – ident: e_1_2_4_7_1 doi: 10.1039/C5BM00532A – ident: e_1_2_4_27_1 doi: 10.1021/j100096a001 – ident: e_1_2_4_6_1 doi: 10.1021/ja071090b – ident: e_1_2_4_9_1 doi: 10.1021/nn201171r – ident: e_1_2_4_20_2 doi: 10.1038/nrc3064 – ident: e_1_2_4_11_2 doi: 10.1016/S1369-7021(11)70161-4 – ident: e_1_2_4_24_4 doi: 10.7150/thno.31914 – ident: e_1_2_4_13_1 doi: 10.1039/C7CS00391A – ident: e_1_2_4_43_1 doi: 10.1111/j.2042-7158.2012.01567.x – ident: e_1_2_4_34_1 doi: 10.1039/b504487a – ident: e_1_2_4_39_1 doi: 10.1039/c000605j – ident: e_1_2_4_24_1 doi: 10.1039/C8CS00271A – ident: e_1_2_4_37_1 doi: 10.1039/c1sc00231g – ident: e_1_2_4_40_1 doi: 10.1111/j.1365-2230.2010.03989.x – ident: e_1_2_4_3_1 doi: 10.1038/nnano.2011.166 – ident: e_1_2_4_35_1 doi: 10.1002/anie.201511432 – ident: e_1_2_4_27_4 doi: 10.1063/1.1677527 – ident: e_1_2_4_29_1 doi: 10.1039/C7CP02110K – ident: e_1_2_4_11_1 doi: 10.1073/pnas.1204600109 – ident: e_1_2_4_19_3 doi: 10.1021/acsami.7b01157 – ident: e_1_2_4_30_1 doi: 10.1016/j.addr.2007.05.006 – ident: e_1_2_4_41_1 doi: 10.1002/chem.200900165 – ident: e_1_2_4_32_1 doi: 10.1016/j.addr.2012.01.015 – ident: e_1_2_4_1_5 doi: 10.1021/acs.chemrev.5b00046 – ident: e_1_2_4_18_1 doi: 10.1021/cr970025p – ident: e_1_2_4_24_3 doi: 10.1007/s10847-014-0412-8 – ident: e_1_2_4_15_1 doi: 10.1039/C2CS35233H – ident: e_1_2_4_27_3 doi: 10.1007/BF00533485 – ident: e_1_2_4_44_1 doi: 10.1038/s41565-018-0146-7 – ident: e_1_2_4_37_2 doi: 10.1021/cr200213s – ident: e_1_2_4_17_1 doi: 10.1039/C8CS00037A – ident: e_1_2_4_14_1 doi: 10.1016/j.addr.2007.05.012 – ident: e_1_2_4_8_3 doi: 10.1021/ar2000259 – ident: e_1_2_4_24_7 doi: 10.1038/s41557-018-0164-y – ident: e_1_2_4_24_2 doi: 10.1111/cbdd.12818 – ident: e_1_2_4_26_1 doi: 10.7150/thno.31653 – ident: e_1_2_4_4_1 doi: 10.1039/C3PY01202F – ident: e_1_2_4_13_5 doi: 10.1039/C7CS90102J – ident: e_1_2_4_22_1 doi: 10.1002/anie.201813397 – ident: e_1_2_4_31_3 doi: 10.1038/nchem.1326 – ident: e_1_2_4_31_2 doi: 10.1039/b813759e – ident: e_1_2_4_10_1 doi: 10.1038/nnano.2010.231 – ident: e_1_2_4_1_7 doi: 10.1038/natrevmats.2016.75 – ident: e_1_2_4_2_1 doi: 10.1038/nmat2992 – ident: e_1_2_4_1_3 doi: 10.1002/wnan.1527 – ident: e_1_2_4_8_1 doi: 10.1021/cr2001178 – ident: e_1_2_4_13_4 doi: 10.1016/j.addr.2008.02.011 – ident: e_1_2_4_21_2 doi: 10.1039/C8CS00304A – ident: e_1_2_4_28_1 doi: 10.1002/wcms.19 – ident: e_1_2_4_27_2 doi: 10.1063/1.464913 – ident: e_1_2_4_19_2 doi: 10.1002/anie.201707164 – ident: e_1_2_4_1_1 doi: 10.1038/s41570-017-0063 – ident: e_1_2_4_45_1 doi: 10.1002/adma.201805697 – ident: e_1_2_4_13_2 doi: 10.1016/S1773-2247(04)50001-1 – ident: e_1_2_4_24_5 doi: 10.1039/c0nj00285b – ident: e_1_2_4_13_6 doi: 10.1039/C6CS00898D – ident: e_1_2_4_20_3 doi: 10.1021/ac5039779 – ident: e_1_2_4_36_1 doi: 10.1007/978-0-387-46312-4 – ident: e_1_2_4_38_1 – ident: e_1_2_4_19_4 doi: 10.1039/C7SC01438D – ident: e_1_2_4_1_6 doi: 10.1002/ijch.201900032 – ident: e_1_2_4_16_1 doi: 10.1021/acs.chemrev.5b00341 – ident: e_1_2_4_19_1 doi: 10.1021/jacs.8b02331 – ident: e_1_2_4_25_1 doi: 10.1021/jo00039a027 – ident: e_1_2_4_13_3 doi: 10.1002/ijch.201100033 – ident: e_1_2_4_33_1 doi: 10.1074/jbc.273.24.14721 – ident: e_1_2_4_8_2 doi: 10.1038/nmat3430 – ident: e_1_2_4_42_1 doi: 10.1016/0022-1759(83)90303-4 |
SSID | ssj0009606 |
Score | 2.6261365 |
Snippet | Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too... Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e1908435 |
SubjectTerms | calixarene Calixarenes Chemical compounds chemotherapy Containers drug delivery Drug delivery systems Drugs Functional groups Hypoxia Materials science Molecular structure Nanomaterials Side effects supramolecular chemistry Tumors |
Title | A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted Therapy |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadma.201908435 https://www.ncbi.nlm.nih.gov/pubmed/32459030 https://www.proquest.com/docview/2423510351 https://www.proquest.com/docview/2407317475 |
Volume | 32 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bS8MwFMeD7EkfvF_mjQiCT90laZr2cXhhCFMYE3wraZKCqNvQTdQnP4Kf0U_iOellmyKCPpamt6TnnP9JT38h5JDzKJG-Ul4irPR8iEFe1Ahc4ZqIjMWwglMDnYugfeWfX4vrqb_4Mz5EOeGGluH8NRq4Sh7rE2ioMo4bBAEthJAPThgLtlAVdSf8KJTnDrbHhRcFflhQGxusPnv4bFT6JjVnlasLPWdLRBU3nVWc3NbGo6SmX7_wHP_zVMtkMdeltJW9SCtkzvZXycIUrXCNXLZoDqmm7Zfh4PlGfby9d_Ma2ydLO8VKuxSRVwr_KqQgiWlvfD94gKY9V3RuDe1lJIN1cnV22jtue_l6DJ7mEnuQiTDQfqplkITcQKImdZJKIaVFkKCyTKU65cxEkGOFqRFScabBRbCm8a2v-Aap9Ad9u0WoaFhtuA58xN-oMFLID26qRBgJCQ7XVeIV4xHrHFaOa2bcxRlmmcXYUXHZUVVyVLYfZpiOH1vuFsMb5-b6GKOoRLSgaFbJQbkbDA2_nqi-HYyxDXhDyN8knGIzey3KS4EqFRG4yyphbnB_uYe4ddJplVvbfzloh8wzzPxd4fAuqYwexnYP5NEo2Xcm8AlLkgV- |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bT9swFICPRvcAPLBx79aBkZB4CrR2HCeP1TZULi1SFSTeIsd2JAS0qLQIeNpP2G_cL5mPc-nKhJDgMYqdOLaPzyXHnwF2GYtS4UvppdwIz7c6yIuagUtc45E2qFYwNNDtBZ1z__iCl9mEuBcm50NUATeUDLdeo4BjQPpgSg2V2oGDrEYLrc6fg494rLfzqvpTghQa6A63x7gXBX5Ychub9GC2_qxe-s_YnLVdnfI5_ARp2ew85-RqfzJO99XTM6Lju77rMywVpilp53NpGT6YwQos_gMsXIWzNik41aTzeDt8uJR_fv3uF2m294Z0y8N2CVKvJG4sJNYqJvHkZjiyRWOXd240iXOYwRqcH_6Mv3e84kgGTzGBXUh5GCg_UyJIQ6atryZUmgkuhEGWoDRUZipjVEfWzQozzYVkVNlVgra0b3zJ1qE2GA7MJhDeNEozFfhIwJFhJBEh3JIp18L6OEzVwSsHJFEFrxyPzbhOctIyTbCjkqqj6rBXlb_NSR0vlmyU45sUEnuXoF2JdEHeqsNOddvKGv5AkQMznGAZuyBaF07YR2zk86J6lTVMeWRXzDpQN7qvtCFp_-i2q6svb6m0DfOduHuanB71Tr7CAsVAgMsjbkBtPJqYb9ZaGqdbTh7-AqUGCZk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bT9swFICPuEgTe2CwwSjjYqRJewq0vsTJY0WpyqUwoSLxFjm2IyGgraBFG0_8BH7jfsl8nAuUaUKCxyh24tg-N-f4M8B3xuJUcqWCVFgZcGeDgrge-sQ1ERuLZgWXBrrHYeeMH5yL82e7-HM-RLXghpLh9TUK-NBkO0_QUGU8N8gZtMiZ_GmY5WE9wnndOn0CSKF_7ml7TARxyKMS21inO5P1J83SP77mpOvqbU_7E6iy1XnKyeX2eJRu6_sXQMf3fNYCzBeOKWnmM2kRpmz_M3x8hiv8AidNUlCqSef3cPDrQv15eDwtkmzvLOmWR-0SZF4p3FZInE9MeuPrwY0r2vNZ59aQXo4yWIKz9l5vtxMUBzIEmknsQSqiUPNMyzCNmHGRmtRpJoWUFkmCylKV6YxRE7sgK8qMkIpR7XQEbRhuuWLLMNMf9O0KEFG32jAdcuTfqChWCBBuqFQY6SIcpmsQlOOR6IJWjodmXCU5Z5km2FFJ1VE1-FGVH-acjv-WXCuHNynk9TZBrxLZgqJRg63qtpM0_H2i-nYwxjJOHboATrpHfM2nRfUq55aK2OnLGlA_uK-0IWm2us3qavUtlTbhw89WOznaPz78BnMUVwF8EvEazIxuxnbduUqjdMNLw1-VVQhR |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+General+Hypoxia-Responsive+Molecular+Container+for+Tumor-Targeted+Therapy&rft.jtitle=Advanced+materials+%28Weinheim%29&rft.au=Zhang%2C+Tian-Xing&rft.au=Zhang%2C+Zhan-Zhan&rft.au=Yue%2C+Yu-Xin&rft.au=Hu%2C+Xin-Yue&rft.date=2020-07-01&rft.eissn=1521-4095&rft.spage=e1908435&rft_id=info:doi/10.1002%2Fadma.201908435&rft_id=info%3Apmid%2F32459030&rft.externalDocID=32459030 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0935-9648&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0935-9648&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0935-9648&client=summon |